Market Research Report
United States Dna Sequencing Market Forecast 2021-2026
|United States Dna Sequencing Market Forecast 2021-2026|
Published: May 24, 2021
Content info: 148 Pages
Delivery time: 2-3 business days
The United States DNA sequencing market is set to register a CAGR of 16.89% during the forecast period, 2021-2026. Technological developments, advanced healthcare infrastructure, and increasing investment in R&D propel market growth in the country.
In the United States, several programs and initiatives facilitate market growth. For instance, the precision medicine initiative cohort program encourages around 1 million participants to enhance their ability to treat and prevent diseases associated with differences in genetics, environment, and lifestyle. Also, universal newborn screening plans are conducted in the country. As per research studies, within 24-48 hours after birth, few blood drops drawn from newborns are sent to labs to screen for life-threatening disorders. Such genome sequence-based diagnostics and government plans are raising market demands in the US.
DNA sequencing has also caused a paradigm shift in proteomic and genomic research. This is attributed to its accuracy and high-throughput technology utilized for varied applications. It is adopted in many academic research institutes. For instance, in June 2020, NovaSeq 6000 Sequencing System was installed by Illumina at the Whitehead Institute for Biomedical Research, Massachusetts. Such factors boost the market growth.
Some of the market's leading players include PerkinElmer Inc, Illumina Inc, Danaher Corporation (Integrated DNA Technologies Inc), Agilent Technologies Inc, Adaptive Biotechnologies Inc, Bio-Rad Laboratories Inc, etc.